Pskov

Researchers are evaluating whether a mobile application can improve how well patients with luminal HER2-negative stage II-III breast cancer stick to their adjuvant therapy using ribociclib combined with an aromatase inhibitor (AI). The app is designed to educate patients about relapse risks and how to prevent and manage side effects. This study looks at treatment adherence and retention in real-world practice. Participants receive adjuvant treatment with ribociclib, a CDK4/6 inhibitor, along with an aromatase inhibitor such as letrozole or anastrozole. Premenopausal patients may also receive a GnRH agonist. The study compares adherence and retention rates between patients who use the mobile app and those who do not, with treatment starting no earlier than 28 days before consent. During the 12-month study period, researchers monitor how many patients remain on ribociclib plus AI therapy. Participants provide informed consent and are followed to assess adherence, retention, and safety. The main outcome measured is the percentage of patients continuing treatment over 12 months, helping to understand if the app supports better therapy adherence.

Researchers are conducting an observational surveillance study to identify the genetic types of rickettsia bacteria causing rickettsioses in patients from various regions of Russia. The study focuses on patients with diagnosed or suspected tick-borne rickettsioses. It aims to link genetic information of the bacteria with patients' medical histories, disease progression, symptoms, and treatments to find clinical patterns specific to different causative agents. The study is non-interventional and has received ethical committee approval. No changes are made to patients' routine treatment or diagnostic procedures during the study. Biological samples such as blood, plasma, buffy coat, serum, or eschar swabs collected during standard diagnostics are used for genetic analysis of the rickettsia species. These residual diagnostic samples are collected only after patients or their legal representatives give written informed consent. Physicians complete individual case report forms to record relevant medical information for each participant. Participants provide informed consent, and their medical history, symptoms, disease course, and treatments are recorded. The genetic typing of rickettsia bacteria is performed within up to 4 weeks after sample collection. The study monitors these genetic findings alongside clinical data to improve understanding of rickettsioses. There is no intervention or alteration in patient care, and the study respects current medical standards throughout its observation period.